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Abstract
Background: R-flurbiprofen, one of the enantiomers of flurbiprofen racemate, is inactive with respect to cyclooxygenase
inhibition, but shows analgesic properties without relevant toxicity. Its mode of action is still unclear.
Methodology/Principal Findings: We show that R-flurbiprofen reduces glutamate release in the dorsal horn of the spinal
cord evoked by sciatic nerve injury and thereby alleviates pain in sciatic nerve injury models of neuropathic pain in rats and
mice. This is mediated by restoring the balance of endocannabinoids (eCB), which is disturbed following peripheral nerve
injury in the DRGs, spinal cord and forebrain. The imbalance results from transcriptional adaptations of fatty acid amide
hydrolase (FAAH) and NAPE-phospholipase D, i.e. the major enzymes involved in anandamide metabolism and synthesis,
respectively. R-flurbiprofen inhibits FAAH activity and normalizes NAPE-PLD expression. As a consequence, R-Flurbiprofen
improves endogenous cannabinoid mediated effects, indicated by the reduction of glutamate release, increased activity of
the anti-inflammatory transcription factor PPARc and attenuation of microglia activation. Antinociceptive effects are lost by
combined inhibition of CB1 and CB2 receptors and partially abolished in CB1 receptor deficient mice. R-flurbiprofen does
however not cause changes of core body temperature which is a typical indicator of central effects of cannabinoid-1
receptor agonists.
Conclusion: Our results suggest that R-flurbiprofen improves the endogenous mechanisms to regain stability after axonal
injury and to fend off chronic neuropathic pain by modulating the endocannabinoid system and thus constitutes an
attractive, novel therapeutic agent in the treatment of chronic, intractable pain.
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Introduction
Persistent intractable pain comes about as a sequel of peripheral
or central nerve injury and is a major health problem.
Conventionally used analgesics are often not sufficiently effective
or their long-term usage is accompanied by side-effects, which
seriously narrow the quality of life and lead to poor compliance
and rejection of therapy. Various novel targets and compounds
have been identified in recent years that might be useful in
neuropathic pain syndromes [1,2]. However, so far none of these
has been approved for clinical use.
Here, we studied the R-enantiomer of a well-known non
steroidal anti-inflammatory drug (NSAID), flurbiprofen-racemate
[3], that has been used for decades as analgesic. Interestingly, R-
flurbiprofen does not inhibit cyclooxygenase activity [4] and has
been considered as the non-functional constituent of marketed
flurbiprofen-racemate. However, R-flurbiprofen reduces inflam-
mation [5] via inhibition of the transcription factor NF-kB [5] and
is essentially free of the side effects typical to classical NSAIDs,
such as gastrointestinal or renal toxicity [6]. Because of the anti-
inflammatory efficacy and essential lack of toxicity R-flurbiprofen
has been evaluated as a potential remedy in Alzheimer’s disease
with some success in clinical trials [7]. R-flurbiprofen also
attenuates nociceptive behavior in rats [8] and pain in humans
[9]. In these species, R-flurbiprofen is not inverted to its
cyclooxygenase inhibiting S-enantiomer. Previously, it has been
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endocannabinoid breakdown [10]. It is unknown whether such
effects occur in vivo. However, it has been shown that inhibition of
endocannabinoid metabolism via specific inhibition of fatty acid
amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL)
reduces pain in inflammatory and neuropathic pain models
[11,12], without producing diverse side effects, such as temporary
memory impairment, addiction and psychotropic effects, which
are associated with agonists at cannabinoid-1 (CB1) receptors in
forebrain circuits.
Since fortification of endogenous pain defense has emerged as a
valuable strategy particularly in chronic pain we probed
antinociceptive mechanisms of R-flurbiprofen in models of
peripheral nerve injury and found that R-flurbiprofen reduces
neuropathic pain in rodents by normalizing pathologically reduced
endocannabinoid levels in DRGs, spinal cord and frontal cortex
without direct CB1-mediated central effects. As a consequence, R-
flurbiprofen reduces glutamate release in the dorsal horn evoked
by nerve injury and prevents the development of the neuro-
aggressive microglia phenotype. The endogenous defense against
pain is thus potentiated, without tolerance or psychotropic side
effects. As R-flurbiprofen is already known to be safe and
neuroprotective in humans it may be used as ‘‘add-on’’ treatment
for chronic neuropathic pain.
Methods
Animals and treatments
All experiments adhered to the guidelines of the Committee for
Research and Ethical Issues of the International Association for
the Study of Pain (IASP), were approved by the local Ethics
Committee for Animal Research (Darmstadt, Germany) and
adhered to the guidelines of GV-SOLAS for animal welfare in
science (permission numbers F95/22, F143/26).
Male Sprague Dawley rats (Charles River, Sulzfeld, Germany)
weighing 150–200 g or 8–12 week old C57Bl6 mice were used in
most experiments. Mice deficient of the cannabinoid CB1 receptor
specifically in a primary sensory neurons (SNS-CB1
2/2)w e r e
generated via cre-loxP-mediated recombination by mating mice
carrying the CB1-flox allele (CB1
fl/fl) with mice expressing cre
recombinase under control of the Nav1.8 promoter (SNS-cre). The
SNS-cre mice enable gene recombination commencing at birth
selectively in Nav1.8-expressing sensory neurons, without affecting
gene expression in the spinal cord, brain or any other organs in the
body [13]. Genotyping was done on mouse genomic tail DNA as
described [13] using primers: for sense strand 59-
GCTGTCTCTGGTCCTCTTCTTAAA-39 and for anti-sense 59-
GGTGTCACCTCTGAAAACAGA-39 to detect CB1 flox allele
and for sense strand 59-GAAAGCAGCCATGTCCAATTTACT-
GACCGTAC-39 and for anti-sense strand 59-GCGCGCCTGAA-
GATATAGAAGA-39 to detect SNS-cre transgene expression.
Littermates were used in all experiments to control for background
effects.
The enantiomers of flurbiprofen (2-(2-fluoro-4-biphenylyl)-
propionic acid) were supplied by PAZ Arzneimittelentwicklungs-
gesellschaft (Frankfurt/Main, Germany). The optical purity of
both enantiomers was .99%. Flurbiprofen enantiomers were
dissolved in phosphate buffer and 2.5, 4.5 or 9 mg/kg were
injected twice daily intraperitoneally or 10 mg/kg/d was admin-
istered perorally in the drinking water. The latter was used in
experiments which assessed the inhibitory effects of the CB1 and
CB2 cannabinoid receptor antagonists, AM251 and AM630
(Cayman Chemicals). The cannabinoid antagonists were dissolved
in 1:1 DMSO/sodium chloride and injected intraperitoneally
(3 mg/kg). Gabapentin (1-(aminomethyl)-cyclohexane acetic acid)
was obtained from Sigma-Aldrich and used at 25 mg/kg per day.
Control animals received the respective vehicles.
Nerve injury models
Surgery was carried out under 1.5–2% isoflurane anesthesia.
For spared nerve injury (SNI), two of the three peripheral
branches of the sciatic nerve, the common peroneal and the tibial
nerves, were ligated with silk (6–0) and distally transected, leaving
the sural nerve intact [14]. For chronic constriction injury (CCI),
we tied three silk ligatures (6–0) around the proximal sciatic nerve
constricting the nerve by about 30–50% [15].
Behavioral experiments
All tests were performed by an investigator blinded for the
treatment or genotype of the animals. After habituation, we
determined the latency for paw withdrawal to von Frey-like
filament using a Dynamic Plantar Aesthesiometer (Ugo Basile,
Italy) to assess mechanical allodynia. The steel rod was pushed
against the paw with linear ascending force (0–50 grams for rats
and 0–5 grams for mice over 10 seconds) until a strong and
immediate withdrawal occurred. The paw withdrawal latency
was the mean of three consecutive trials with intervals of at least
30 sec. To measure cold allodynia, we recorded the latency for
paw withdrawal, paw licking or jumping after placing rats or mice
onto a Cold Plate held at 5uC (AHP-1200CPHC, Teca, USA)
and by employing the acetone test. The time rats or mice spent
licking, lifting or shaking the nerve injured paw after application
of a drop of acetone to the plantar side were recorded for a
period of 90 seconds starting right after acetone application. Heat
hyperalgesia was assessed by recording temperature withdrawal
thresholds on a Hot Plate which allows for temperature gradient
analyses. The starting temperature was set at 28uC and increased
by 10uC per minute up to paw withdrawal. The cut off
temperature was 54uC.
Core temperature
Mouse telemetry was used to analyze the time courses of mouse
body temperature. Two days before analysis a radio telemetry
transmitter (Emitter 4000 system, Mini Mitter, Bend, OR) was
inserted into the intraperitoneal cavity for continuous recording of
the core body temperature under isoflurane anesthesia. For
Figure 1. Time course of the nociceptive behavior in the Spared Nerve Injury (SNI, left panel) and the Chronic Constriction Injury
(CCI, right panel) model of neuropathic pain. Rats were treated with R-flurbiprofen, S-flurbiprofen, gabapentin or vehicle (n=6 per group). The
daily treatment (twice daily i.p.) started 10 days after nerve injury. a Mechanical hyperalgesia was assessed by recording the paw withdrawal
threshold to stimulation with a Dynamic Plantar Aesthesiometer, b mechanical allodynia as paw withdrawal threshold to von Frey hairs, c, d cold
allodynia as response time in the acetone test and e, f cold hyperalgesia by counting withdrawal reactions during exposure to a cold plate at 2uC.
Comparison of the areas under the effect x time curves revealed statistically significant differences between R-flurbiprofen and gabapentin treated
animals compared with vehicle or S-flurbiprofen. For R-flurbiprofen 4.5 or 9 mg/kg twice daily provided statistically significant antinociceptive effects.
For SNI, respective P values were 0.002 for mechanical, 0.026 for cold allodynia, 0.018 for cold hyperalgesia. For CCI, P values were 0.001 mechanical,
0.041 cold allodynia, n.s. for cold hyperalgesia.
doi:10.1371/journal.pone.0010628.g001
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telemetry signals emitted by the implanted transmitter were
continuously monitored in intervals of 5 min using the Vital view
software (Mini Mitter). After 60-min baseline recordings drugs or
vehicle were injected and the temperature recorded for further
3.5 hours.
Spinal cord microdialysis
Microdialysis was employed to assess glutamate release in the
dorsal horn of the spinal cord. A dialysis probe was constructed
from a polyacrylonitrile hollow fiber (AN69, OD 200 mm;
molecular mass cutoff ,40 kDa; Hospal, Germany), a polyeth-
ylene (PE) inlet tube (ID 0.26 mm, OD 0.6 mm) and a micro pin
for insertion. We inserted the catheter during 1.5–2% isoflurane
anesthesia through vertebra Th13 after drilling a small hole,
which approximates L4-L5 in the rat lumbosacral spinal cord, as
described [16]. The catheter was connected to a CMA 100
microdialysis pump and perfused with artificial cerebrospinal
fluid (ACSF, composed of (in mM): 141.7 Na
+,2 . 6K
+,0 . 9M g
2+,
1.3 Ca
2+, 122.7 Cl
2,2 1H C O 3
2, 2.5 HPO4
22, and 3.5 dextrose,
aerated with 5% CO2 in 95% O2 to adjust pH to 7.2) at a flow
rate of 1 ml/min. During a 90 min dialysis equilibration period
anesthesia was switched to urethane (1.2 g/kg i.p.). At the end of
baseline sampling of dialysates (1265 min intervals) we exposed
the mid sciatic nerve and transected it for axotomy or applied 1%
capsaicin cream manufactured by the local pharmacy directly
onto the nerve. Small sponges prevented leakage into surround-
ing tissue. The wound was loosely closed to prevent desiccation
and dialysates sampled for 1465 min intervals. At completion,
the correct placement of the microdialysis catheter (dorsal
horn, L4/5) was confirmed by dye injection and microscopic
inspection.
We analyzed glutamate dialysate concentrations with a CMA
600 Analyzer (CMA, Stockholm, Sweden) according to the
manufacturer’s instructions. The device is used for routine clinical
analysis of dialysate glutamate concentrations employing a
glutamate oxidase/peroxidase two-step enzymatic assay and
subsequent photometric quantification of the end-product quino-
nediimine at 546 nm (lower detection limit 1 mM).
Microarray hybridization and quantitative RT-PCR
Total RNA was extracted from homogenized tissue according
to the protocol provided in the RNAeasy tissue Mini Kit (Qiagen,
Hilden, Germany), reverse transcribed using poly-dT as a primer
to obtain cDNA fragments. cDNA fragments were amplified by
PCR and cloned into the pCR4 vector (TA cloning Kit,
Invitrogen). Biotinylated cRNA was produced by in vitro
transcription and used for hybridization on the Affymetrix
RGU34A chip as described [17,18]. The data are MIAM
compliant.
Quantitative real-time PCR was performed using the Sybrgreen
detection system with primer sets designed on Primer Express.
Specific PCR product amplification was confirmed with gel
electrophoresis. Transcript regulation was determined using the
relative standard curve method per manufacturer’s instructions
(Applied Biosystems). For each time point 3 samples of pooled
tissue of 3 animals was analyzed.
Western blot analysis and enzyme immune assays
Tissue samples were homogenized in PhosphosafeH (Novagen)
cell lysis and extraction buffer, centrifuged at 16000 rpm for
5 min and the supernatant transferred to a new tube. For
cannabinoid receptor extraction the Compartmental Protein
Extraction Kit (Millipore) was used. Proteins were separated by
SDS-PAGE (30 mg/lane) and transferred onto nitrocellulose
membranes (Amersham Pharmacia Biotech) by wet-blotting.
The blots were incubated with primary antibodies directed
against CB1 (1:500, Cayman Europe), CB2 (1:500 Cayman
Europe), FAAH (1:1000, SantaCruz Biotechnology), NAPE-PLD
(1:500, Novus), Iba-1 (1:500; Wako, Neuss, Germany), phospho-
p38 and total p38 (Cell Signaling), CD68 (Abcam), beta-actin
(SantaCruz Biotechnology), Hsp90 (SantaCruz Biotechnology) or
extracellular signal-regulated kinase 2 (ERK-2; 1:10000; Santa-
Cruz Biotechnology) according to standard procedures. ERK-2,
HSP-90 or beta-actin served as loading controls. After incubation
with secondary antibodies conjugated with IRDye 680 or 800
(1:10000; LI-COR Biosciences, Bad Homburg, Germany), blots
were visualized and analyzed on the Odyssey Infrared Imaging
System (LI-COR Biosciences). Triplicate experiments and
duplicate blots each were obtained. The ratio of the respective
protein band to the loading control was used for semi-
quantitative analysis. Signal intensity of phospho-p38-immuno-
reactive bands was normalized relative to total p38. To further
quantify p38 phosphorylation by EIA, we used a TiterZyme
Enzyme Immunometric Assay Kit (AssayDesigns) following
instructions provided by the manufacturer.
For analysis of PPARc activity we employed a transcription
factor assay kit (Actif Motif) that allows for the detection and
quantification of transcription factor activation by a combination
of specific oligonucleotide binding and subsequent detection with a
specific antibody. Nuclear extracts were prepared from DRGs,
spinal cord and forebrain cortex using a Nuclear-Cytosol
Fractionation Kit (PromoKine) and were then analyzed with the
PPARc-kit as recommended by the manufacturer.
Endocannabinoid analysis
Tissue pieces of 1–2 mg were weighed, homogenized and
extracted by liquid-liquid extraction and the reconstituted
samples were analyzed for arachidonoyl ethanolamide (ananda-
mide, AEA), palmitoyl ethanolamide (PEA), 2-arachidonoylgly-
cerol (2-AG), 1-arachidonoylglycerol (1-AG) and oleoyl ethano-
lamide (OEA). The respective deuterated substances AEA-d8,
PEA-d4, 2-AG-d5, 1-AG-d5 and OEA-d2 were used as internal
standards. We performed 2 cycles of ethylacetate extraction.
800 ml of ethylacetate was added to the homogenate, vortexed
and centrifuged for 5 min at 10,000 g. The organic phase was
Figure 2. Time course of the nociceptive behavior in nerve-injured and naı ¨ve rats treated with R-flurbiprofen or vehicle (n=6 per
group) and glutamate release in the dorsal horn of the spinal cord. a In SNI, the daily drug treatment started the day after nerve injury.
Mechanical hyperalgesia was assessed by recording the paw withdrawal threshold to stimulation with a Dynamic Plantar Aesthesiometer, b cold
allodynia as paw withdrawal latency after exposure to a 10uC cold plate. Comparison of the areas under the effect x time curves revealed statistically
significant differences between R-flurbiprofen and vehicle treatment (P,0.05). c In naı ¨ve rats mechanical sensitivity was assessed with a Dynamic
Plantar Aesthesiometer, and d heat sensitivity as withdrawal latency to noxious heat stimulation in the Hargreaves test. R-flurbiprofen was injected at
time zero, it had no effect. e Time course of glutamate release in the dorsal horn of the lumbar spinal cord in rats treated with 9 mg/kg R-flurbiprofen
i.p. or vehicle 30 min before application of capsaicin cream (0.1%) onto the exposed sciatic nerve (time ‘‘zero’’). Glutamate was analyzed in
microdialysates from the dorsal horn in a colorimetric enzyme assay. The peak glutamate release after capsaicin application differed significantly
between the treatment groups (n=6; P,0.05).
doi:10.1371/journal.pone.0010628.g002
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were combined and evaporated at a temperature of 45uCu n d e r
a gentle stream of nitrogen. The residues were reconstituted
with 100 ml of methanol, frozen at 220 degrees for 12 hours,
and centrifuged for 5 min at 10,000 g. The residues were
transferred in glass vials and 20 ml were injected into the LC-
MS/MS system.
HPLC analysis was done under gradient conditions using a
Luna HST C18 column (100 mm L62 mm ID, 2.5 mm particle
size, Phenomenex, Aschaffenburg, Germany). MS and MS/MS
analyses were performed on an API 5000 triple quadrupole mass
spectrometer with a Turbo V source (Applied Biosystems,
Darmstadt, Germany) in the negative ion mode. Precursor-to-
product ion transitions of m/z 346R259 for AEA, m/z 354R86
for AEA-d8, m/z 298R268 for PEA, m/z 302R272 for PEA-d4,
m/z 377R303 for 2-AG and 1-AG, m/z 382R303 for 2-AG-d5
and 1-AG-d5, m/z 324R86 for OEA, and m/z 326R86 for
OEA-d2 were used for the multiple reaction monitoring (MRM)
with a dwell time of 75 ms. Concentrations of the calibration
standards, quality controls and unknowns were evaluated by
Analyst software (version 1.4; Applied Biosystems, Darmstadt,
Germany). Variations in accuracy and intra-day and inter-day
precision (n=6 for each concentration, respectively) were ,15%
over the range of calibration.
Figure 3. Expression and activity of fatty acid amide hydrolase (FAAH) and NAPE-PLD in DRGs and spinal cord after nerve injury. a,
b Time course of FAAH mRNA levels in the L5 DRGs and the dorsal horn of the lumbar spinal cord ipsi lateral to a sciatic nerve lesion in three different
models of neuropathic pain, i.e. the spared nerve injury, SNI, the chronic constriction injury, CCI and the spinal nerve ligation, SNL analyzed by
Affymetrix U34 microarray in triplicate. Pooled samples of three animals each were used. The asterisks indicate statistically significant results with
P,0.05. c Results were confirmed in the SNI model in mice by quantitative RT-PCR and d protein analysis in Western Blots. e Concentration
dependent in vitro inhibition of recombinant FAAH by R-flurbiprofen and the FAAH specific inhibitor URB597 f QRT-PCR and Western Blot analysis of
NAPE-PLD mRNA and protein expression in DRGs 7 days after SNI and treatment with R-flurbiprofen 4.5 mg/kg twice daily or vehicle. For QRT-PCR
and Western Blot analysis pooled samples of each 3 mice were used and two independent experiments were performed. Mice were treated with
4.5 mg/kg R-flurbiprofen or vehicle twice daily (representative images; n=6 per group).
doi:10.1371/journal.pone.0010628.g003
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PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10628Figure 4. Modulation of endocannabinoid levels by R-flrubiprofen in microglial cells (EOC20) and tissue. a Endocannabinoids in EOC20
at baseline and after stimulation with LPS (1 mg/ml) with or without treatment with R-flurbiprofen (10 mM); n=6 experiments per group. b
Endocannabinoids in ipsi lateral L4/5 DRGs, c ipsi lateral dorsal horn of the spinal cord d and contra lateral forebrain cortex in the SNI model 7 days
after nerve injury and treatment with 4.5 mg/kg R-flurbiprofen or vehicle twice daily in mice (n=8 per group; P,0.05). AEA, anandamide; OEA,
R-Flurbiprofen & Cannabinoids
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Terminally anesthetized mice were transcardially perfused with
0.9% saline followed by 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffered saline (PBS, pH 7.4). The L4 and L5 spinal
cord segments, L4 and L5 DRGs and sciatic nerves were dissected,
postfixed for 2 h in PFA and transferred into sucrose (20% in PBS)
for overnight cryoprotection at 4uC. We embedded the tissue in
Tissue-TekH O.C.T. Compound (Science Services, Munich,
Germany) and cut 14 mm transverse sections of DRGs on a
cryotome and mounted them on glass slides. Spinal cord tissue was
sectioned at 30 mm on a vibratome and free floating sections were
used for immunostainings. Sections were permeabilized for 5 min
in PBST (0.1% Triton X-100 in PBS), blocked for 1 h with 10%
normal goat serum and 3% bovine serum albumin (BSA) in PBST
or with 1% blocking reagent (Roche Diagnostics) in PBST, and
incubated overnight at 4uC with primary antibodies (IBA-1
DAKO, GFAP and NeuN Chemicon, CD11b Serotec, CD68
Abcam, CB1 Frontier Sciences) dissolved in 3% BSA or 1%
blocking reagent in PBST. After washing in PBS, sections were
incubated for 2 h at room temperature with species-specific
secondary antibodies conjugated with Alexa Fluor 488 or 350
(Invitrogen, Karlsruhe, Germany) or Cy3 (Sigma-Aldrich, Mu-
nich, Germany). After immunostaining, slides were immersed for
5 min in 0.06% sudan black B (in 70% ethanol) to reduce
lipofuscin-like autofluorescence [19], rinsed in PBS and cover
slipped in Flouromount G (Southern Biotech, Birmingham, AL).
Images were obtained using an Eclipse E600 microscope (Nikon,
Du ¨sseldorf, Germany) equipped with a Kappa DX 20 H camera
and Kappa Image Base software (Kappa, Germany). Confocal
images were obtained with a Zeiss LSM 510 laser scanning
microscope (Zeiss, Germany).
Image analysis
We used ImageJ software (version 1.39, National Institutes of
Health) for quantification of CD11b immunoreactivity. The
observer was blinded for the treatment. The mean pixel values
per area were determined from 5 not overlapping areas in the
dorsal horn using the polygon tool and background-corrected.
Results are expressed as mean pixel intensity of each group and
statistically compared by Student’s t-test, P,0.05.
Statistics
We used SPSS 17.0 for statistical evaluation. Data are presented
as means 6 SEM (behavior data) or SD (biochemical data). To
compare the neuropathic pain behavior between groups we
calculated the area under the nociception versus time curve (AUC)
and subjected AUCs to one-way ANOVA of Student’s t-tests.
Immunostaining and western blot results were analyzed with
Student’s t-tests. P was set at 0.05 for all statistical comparisons.
Results
R-flurbiprofen reduces neuropathic pain-like behavior
We analyzed the effects of R-flurbiprofen in two rat models of
neuropathic pain, the Spared Nerve Injury (SNI) and the Chronic
Constriction Injury (CCI) model over two separate application
regimes - first, at the onset of neuropathy and second, after
neuropathic pain reached peak levels. In both models, neuropathy
evokes a marked hypersensitivity to heat, cold and pressure,
resulting in pain in response to innocuous stimuli (allodynia).
Compared to vehicle or S-flurbiprofen, R-flurbiprofen-treated
animals demonstrated a significant reversal of nociceptive
thresholds towards normal pre-injury levels in the SNI (Fig. 1 a,
c, e) as well as the CCI model (Fig. 1 b, d, f), showing that
nociceptive hypersensitivity towards mechanical and cold stimu-
lation was significantly ameliorated. The antinociceptive efficacy
of R-flurbiprofen was dose-dependent and comparable with effects
of gabapentin, which is one of the most effective drugs in the
therapy of neuropathic pain. We observed therapeutic effects at
daily doses of 264.5 and 269 mg/kg R-flurbiprofen (P,0.05). In
both models, antinociceptive efficacy was achieved after full
development of allodynia (Fig. 1). Allodynia was also prevented if
treatment started directly after the nerve lesion (Fig. 2 a, b;
P,0.001 mechanical; P=0.029 cold allodynia). R-flurbiprofen did
not change the sensitivity to mechanical or thermal stimulation in
naı ¨ve animals, indicating lack of effects on normal sensory
functions (Fig. 2 c, d). As expected, the S-enantiomer, S-
flurbiprofen, produced gastrointestinal toxicity due to cyclooxy-
genase inhibition so that the treatment had to be stopped after
seven days in several animals. In contrast, as shown previously [8],
gastrointestinal toxicity did not occur with R-flurbiprofen as
assessed by macroscopic inspection of the gastric mucosa at the
end of the treatment period (data not shown).
R-flurbiprofen reduces nerve injury evoked glutamate
release in the spinal cord
Excessive and sustained glutamate release in the spinal cord
contributes to the development of neuropathic pain [20,21] and is
inhibited by activation of presynaptic cannabinoid CB1 receptors
[22]. We therefore analyzed by in vivo microdialysis whether R-
flurbiprofen modifies stimulated glutamate release in the dorsal
horn of the spinal cord. Baseline glutamate levels were similar in
vehicle and R-flurbiprofen treated rats. Application of capsaicin,
a nociceptive irritant and agonist at TRPV1, onto the sciatic
nerve evoked an immediate glutamate raise, that was maintained
for at least one hour and characterized by a double-peak (Fig. 2
e), as shown previously for formalin-evoked glutamate release
[23]. R-flurbiprofen treated rats demonstrated a significant
reduction in capsaicin-evoked glutamate release (Mann Whitney
U comparison of peak release, P=0.05; Fig. 2 e). We used
capsaicin stimulation instead of axotomy in these experiments
because capsaicin provides a longer lasting, more robust raise of
glutamate [20].
Effects of R-flurbiprofen on nerve injury evoked
alterations of endocannabinoid synthesis and
metabolism
The fast and sustained relief of behavioral correlates of
neuropathic pain directly following R-flurbiprofen administration
in vivo and the suppression of capsaicin-evoked glutamate release
oleylethanolamine; PEA, palmitoylethanolamine; 1AG and 2AG, 1- and 2-arachidonoylglycerol were analyzed by LC-MS/MS. P,0.05 for all tests. e
PPARc activity in nuclear protein extracts of L4/5 DRGs, spinal cord and forebrain cortex in naı ¨ve mice and in nerve injured mice 7 days after SNI. Mice
were treated with vehicle or 4.5 mg/kg R-flurbiprofen twice daily. Results represent pooled extracts of 6 mice in each group. f Core body temperature
in mice (mean 6 s.e.m. shadowed area) treated with the CB1 agonist, WIN55,212-2, the FAAH inhibitor URB597, R-flurbiprofen and respective vehicles
(n=6 per group). Vehicles 10% or 50% DMSO did not produce changes of the core temperature as compared to phosphate buffered saline and were
summarized. The decrease of core temperature in vehicle treated mice is caused by resting during the day. Hypothermia in mice is defined as core
temperature ,35uC.
doi:10.1371/journal.pone.0010628.g004
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10628Figure 5. Time course of the nociceptive behavior in the SNI model of neuropathic pain in mice deficient of the CB1 receptor in DRG
neurons (SNS-CB1
2/2) compared with control mice carrying the floxed CB1 alleles (CB1
fl/fl). Mice were treated with R-flurbiprofen
(4.5 mg/kg twice daily) or vehicle (n=8 per group). The daily drug treatment started the day after nerve injury. a Mechanical hyperalgesia was
assessed by recording the paw withdrawal latency to stimulation with a Dynamic Plantar Aesthesiometer, b cold hyperalgesia as counts of paw
withdrawal reactions after exposure to a 4uC cold plate. Comparison of the time courses by ANOVA revealed statistically significant differences
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PLoS ONE | www.plosone.org 9 May 2010 | Volume 5 | Issue 5 | e10628by R-flurbiprofen suggested a mechanism with rapid onset and
creating a lasting impact on the underlying pathophysiology, both
in line with the hypothesis of cannabinoid mediated effects. In a
microarray screen of gene regulation in the DRGs and spinal cord,
we found a long lasting upregulation of FAAH expression in the
DRGs in three models of sciatic nerve injury (Fig. 3 a) associated
with a drop of endocannabinoids. In the dorsal horn of the spinal
cord, FAAH mRNA levels were slightly reduced at 3 days and
subsequently returned to baseline levels (Fig. 3 b). We confirmed
the time course of FAAH regulation in DRGs and spinal cord after
SNI at the level of mRNA via quantitative RT-PCR (Fig. 3 c) and
protein via Western Blot analysis (Fig. 3 d). At high concentrations
R-flurbiprofen inhibited the activity of recombinant, purified
FAAH; the IC50 of R-flurbiprofen was 1580 mM (CI 95%: 809.0
to 3096) as compared to an IC50 of 1.71 mM for the specific FAAH
inhibitor, URB597 (CI 95%: 1.150 to 2.552) (Fig. 3 e). Although,
in vitro data with recombinant enzyme cannot be directly translated
into in vivo efficacy, it appears unlikely that direct inhibition of
FAAH enzymatic activity is the only mechanism by which R-
flurbiprofen attenuates neuropathic pain.
Despite weak FAAH inhibition, R-flurbiprofen significantly
increased anandamide levels in unstimulated and LPS-stimulated
microglia in vitro (Fig. 4 a). The levels of palmitoylethanolamine
(PEA) and oleylethanolamine (OEA) that are also metabolized by
FAAH were only increased in LPS-stimulated cells. Owing to
these intriguing observations, we analyzed N-arachidonoyl-
phosphatidylethanolamine phospholipase D (NAPE-PLD), the
enzyme involved in anandamide synthesis. Anandamide is
generated through phosphodiesterase-mediated cleavage of a cell
membrane phospholipid precursor, N-arachidonoyl-phosphati-
dylethanolamine (NAPE) which is generated by the enzymatic
transfer of arachidonic acid to the amine group of phos-
phatidyl-ethanolamine. NAPE cleavage to anandamide is cata-
lyzed by NAPE-PLD [24]. RT-PCR and Western Blots
revealed a decrease in NAPE-PLD expression in DRG neurons
after sciatic nerve injury (Figures 3 f). This downregulation
was completely prevented in R-flurbiprofen-treated animals
(Figures 3 f).
As a result of the adaptations of cannabinoid synthesizing and
metabolizing enzymes after nerve injury, we observed that levels of
anandamide, OEA and PEA in the DRGs were considerably
reduced by about 50% after sciatic nerve injury (ANOVA
P,0.001 for AEA, P=0.045 for OEA and P=0.027 for PEA).
We analyzed the endocannabinoids in the DRG and not at the site
of nerve damage because the latter is confounded by the
endocannabinoid levels of infiltrating leukocytes in the periphery
and dominated by 2-AG [13]. The observed drop of endocanna-
binoid levels in the DRGs was evident at 7 days after nerve injury
(Fig. 4 b). It was maintained for at least 5 weeks (Fig. 5 c), i.e.
lasting longer than the down-regulation of cannabinoid-1 receptor
in the DRGs, which had a maximum at 3–7 days and then
gradually returned to normal levels (Suppl. Fig. S1 a, S1 b). In the
spinal cord dorsal horn and forebrain, anandamide levels showed
a similar decrease as in the DRGs (Fig. 4 c, d) despite the observed
drop of FAAH expression (Fig. 3). OEA, PEA and 2-AG were not
significantly reduced. At both sites, R-flurbiprofen treatment
restored anandamide levels, but did not increase endocannabi-
noids above normal naı ¨ve levels. To further assess the in vivo
relevance we analyzed the activity of the anti-inflammatory
transcription factor PPARc which is activated by cannabinoids
and found that R-flurbiprofen increased PPARc activity in DRGs
and spinal cord (Fig. 4e). From these results, we infer that R-
flurbiprofen caused a restoration of endocannabinoid levels, which
were diminished following nerve injury, and therefore likely led to
a better utilization of available CB1 receptors, without causing
excessive cannabinergic activation. To confirm the lack of central
CB1-mediated effects after R-flurbiprofen, we measured body
temperature. Activation of brain CB1 receptors causes a
characteristic hypothermia (temperature ,35uC) (Fig. 4 f), a
sensitive indicator of cannabinergic side effects. R-flurbiprofen had
no effect on body temperature.
Effects of R-flurbiprofen in SNS-CB1
2/2 mice and effects
of CB1 and CB2 receptor antagonists
To further evaluate whether the antinociceptive effects of R-
flurbiprofen were mediated through normalization of endoge-
nous cannabinoids in nociceptive neurons, we tested its
antinociceptive efficacy in mice lacking the CB1 receptor
selectively in primary afferent DRG neurons. These mice were
generated as described [13] by mating mice carrying two CB1-
floxed alleles (CB1
fl/fl) [25] with mice that express cre-
recombinase under control of the promoter of the SNS gene
(SNScre) [13]. SNS codes for the voltage-dependent sodium
channel Nav1.8, which is exclusively expressed in peripheral
neurons of dorsal and trigeminal ganglia [26]. Following nerve
injury, SNS-CB1
2/2 mice show enhanced nociceptive behavior
compared with that of CB1
fl/fl-mice [13]. Treatment of both
SNS-CB1
2/2 and CB1
fl/fl with R-flurbiprofen resulted in a
significant reduction of the nociceptive responses towards
mechanical stimulation (P=0.001 and P,0.001, respectively;
Fig. 5 a, b). With respect to cold stimulation, R-flurbiprofen
significantly reduced nociceptive behavior in CB1
fl/fl mice
(P=0.036), but not in SNS-CB1
2/2 mice (P=0.315). R-
flurbiprofen restored anandamide levels in SNS-CB1
2/2 and
CB1
fl/fl m i c et oac o m p a r a b l ed e g r e ea si nw i l dt y p ea n i m a l s
(Fig. 5 c). To further test cannabinoid mediated effects we used
specific antagonists at CB1 and CB2 receptors, AM251 and
AM630, respectively (Fig. 5d, e, f). Mice were treated after SNI
with R-flurbiprofen or vehicle. A combination of both drugs
(3 mg/kg, single dose) was then injected i.p. in R-flurbiprofen
treated mice (indicated by a black arrow). The cannabinoid
receptor blockage completely abolished the antinociceptive
effect of R-flurbiprofen in tests for heat (5d) and mechanical
hyperalgesia (5e) and cold allodynia (5f), with partial recovery of
R-flurbiprofen mediated antinociception within the following 2
days. The cannabinoid receptor antagonists did not evoke
hypernociception at the respective doses in vehicle treated mice.
between R-flurbiprofen and vehicle treatment in CB1
fl/f mice in both tests. In SNS-CB1
2/2 mice R-flurbiprofen significantly reduced mechanical
hyperalgesia but not cold hyperalgesia (n=8 per group, P,0.05). The grey hatched areas indicate the difference in R-flurbiprofen and vehicle treated
SNS-CB1
2/2 mice. c Anandamide (AEA) levels in L4/5 DRGs and dorsal horn of the spinal cord in SNS-CB1
2/2 and CB1
fl/fl mice treated with R-
flurbiprofen or vehicle (n=8, * indicates P,0.05). 5d, e, f Effects of CB1 and CB2 cannabinoid receptor antagonists, AM251 and AM630, respectively
on R-flurbiprofen mediated antinociception after nerve injury in the SNI model. R-flurbiprofen or vehicle was continuously administered in the
drinking water starting after SNI surgery up to the end of the observation period. Fifteen days after SNI AM251 (3 mg/kg) and AM630 (3 mg/kg) were
injected i.p. in R-flurbiprofen treated mice (black arrow) and heat (d), mechanical (e) and cold (f) pain analyzed 1 and 3 hours after AM251 and AM630
injection (grey area). To assess effects of AM251 and AM630 alone the drugs were injected (each 3 mg/kg) in vehicle treated mice at day 17 (white
arrow) and nociception analyzed 1 and 3 hours after drug injection.
doi:10.1371/journal.pone.0010628.g005
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As described above, R-flurbiprofen normalized endocannabi-
noid levels in the DRGs, most likely leading to improved neuronal
CB1-mediated antinociceptive effects. As the deficiency of the
CB1 receptors in peripheral nociceptive neurons of the DRG did
not completely abolish the antinociceptive effect of R-flurbiprofen,
whereas a combination of a CB1 and a CB2 inhibitor
accomplished full antagonisms, we further investigated potential
effects at CB2 receptors. CB2 is expressed on microglia in the
spinal cord [27]. The activation of spinal cord microglia after
peripheral nerve injury contributes to the development of
neuropathic pain [28]. Agonists at CB2 receptors presumably
prevent this activation by inhibition of cytokine production [29].
We therefore analyzed effects of R-flurbiprofen in terms of
microglia activation. We found the typical microglia activation
after nerve injury, as assessed by immunoreactivity for Iba-1
(Fig. 6, Suppl. Fig. S1 c), CD68 (Fig. 7 d, e) and CD11b (Fig. 7 f, g)
in vehicle treated mice and mitigated in R-flurbiprofen-treated
mice. Overall Iba-1 immunoreactivity was slightly reduced with R-
flurbiprofen treatment (Fig. 7 a) as revealed by Western Blot
analysis on spinal dorsal horn tissue. More strikingly however, R-
flurbiprofen-treated mice predominantly demonstrated microglia
with a ramified morphology whereas the control animals presented
with the typical amoeboid microglia, indicative of the activated
phagocytic phenotype (Fig. 6 i, j and inserts, k, l). In addition, R-
flurbiprofen significantly reduced the activation of p38 MAP
kinase in the spinal cord dorsal horn as revealed by quantitative
phospho-p38 analysis (Fig. 7 b, c). Phospho-p38 is considered to be
a marker for activated microglia [30,31,32,33,34,35,36]. S-
flurbiprofen had no effect on phopho-p38, supporting the specific
role of the R-enantiomer. R-flurbiprofen strongly reduced the
nerve injury evoked increase of CD68 and CD11b immunoreac-
tive microglia in the dorsal horn (Fig. 7d–g). CD11b is part of the
complement 3 receptor and is a marker for microglia. CD68 is a
transmembrane 37 kDa glycosylated protein expressed by tissue
macrophages and activated microglia [36]. It plays a role in
phagocytic activities of tissue macrophages, both in lysosomal
metabolism and extracellular cell-cell interactions. Depending on
glycosylation molecular masses differ. In brain and spinal cord
extracts the antibody detects a band at about 65 kDa in Western
Blot analyses according to the data provided by the manufacturer.
R-Flurbiprofen also reduced the nerve injury-evoked activation
of astrocytes in the dorsal horn (Suppl. Fig. S2). Astrocytes express
CB1 receptors and are activated by endocannabinoids released by
neurons [37]. Astrocytic CB1 activation in vitro modulates
phospholipase C, MAP kinase pathways and chemokine release
from astrocytes [37,38], which contribute to the enhancement of
neuropathic pain [39,40].
Discussion
We demonstrate that R-flurbiprofen reduces nociceptive
behavior in two models of neuropathic pain by restoring
diminished endocannabinoid levels in nociceptive neurons and
pain associated brain centers. The nerve injury-evoked endocan-
nabinoid reduction resulted from an imbalance of endocannabi-
noid synthesis and breakdown after axonal injury. Our data
suggest that by restoring endocannabinoids, R-flurbiprofen allows
for a better utilization of endogenous pain defense mechanisms
mediated through the neuronal CB1 as well as the microglial CB2
receptors.
Because of the combined increase of peripheral CB1 receptor
activation and CB2-mediated silencing of activated microglia, R-
flurbiprofen retained its antinociceptive efficacy despite a temporal
downregulation of CB1 receptors in primary afferent neurons after
axonal injury. As R-flurbiprofen is not a direct agonist at CB1 or
CB2 receptors but appears to act by increasing endocannabinoid
levels, its effects are unlikely to be subject to the development of
centrally mediated psychotropic side effects, supported by the lack
of changes in body temperature which is the most sensitive
parameter in rodents for typical CB1-mediated effects in the brain.
Increased synthesis of NAPE, the precursor of anandamide was
suggested to represent a cytoprotective response in relation to
various forms of neurotoxicity [41]. We therefore propose that R-
flurbiprofen may be a promising analgesic treatment in patients
with neuropathic pain or an interesting lead compound in the
research of endocannabinoid-modulating drugs.
Our results revealed a disturbance of the endocannabinoid
mediated pain defense following axonal injury, which may result
from the loss of the axonal transport of growth factors from the
innervated target organ to the neuronal body. A similar disturbance
has been demonstrated previously for the endogenous opioid system
[42]. The additive effects of disturbances of both the opioid and
endocannabinoid-mediated endogenous inhibition of pain probably
contribute to the therapeutic difficulties in achieving sufficient pain
relief, particularly for intractable clinical manifestations such as cold
and tactile allodynia. The observed deregulation would be also
compatible with the astonishing benefits frequently provided by
cannabinoid treatment in patients with immune cell and microglia
activation and auto-immune mediated neuronal pathology, such as in
multiple sclerosis [43,44] or Huntington’s disease [45]. Interestingly,
a similar decrease of anandamide as a result of increased FAAH
activity was recently found in the paw skin in bone cancer bearing
mice [12]. However, in contrast to nerve injury, bone cancer was
associated with an increase of CB1 receptor expression in the DRGs
[12] as previously shown for inflammatory models [13], suggesting
that normalization of AEA disturbances through FAAH inhibition
may be even more effective in the relief of cancer pain than
neuropathic pain.
We found no effect of S-flurbiprofen on nociceptive behavior or
microglial activation as assessed by phopho-p38 activity. In
addition, S-flurbiprofen exerted considerable gastrointestinal
toxicity due to potent cyclooxygenase inhibition. We can exclude
that the effects of R-flurbiprofen require cyclooxygenase inhibi-
tion. The observed effects are also unlikely to depend on the
previously shown NF-kB inhibition [5], which rather exerts
neuroprotection in dorsal horn neurons after peripheral nerve
injury [46], than promotion of neuroinflammation [47]. The
effects of R-flurbiprofen on the microglia phenotype and
activation state were stronger than suggested by the exclusive
modulation of anandamide in the dorsal horn. However, the
subsequent activation of PPARc may further fortify the anti-
inflammatory effects.
Figure 6. Immunofluorescence analysis of microglia in the spinal cord dorsal horn seven days after nerve injury. Microglia was
identified by Iba-1 immunoreactivity (green). Mice were treated with R-flurbiprofen (4.5 mg/kg twice daily, left panel) or vehicle (right panel). Figures
show the side ipsi lateral to the nerve lesion (a, c, e, f, g, h, i, j, k, l) and the contra lateral side (b, d). The inserts in i and j are z-projections. In I, J
neurons were visualized by NeuN immunofluorescence (red). In k, l astrocytes were stained for glial fibrillary acidic protein (GFAP, red). Scale bars:
100 mm in a–f; 50 mm in g–l; 20 mm in the inserts of I, j.
doi:10.1371/journal.pone.0010628.g006
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PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10628Figure 7. Quantitative analysis of microglia marker proteins in the dorsal horn of the spinal cord. a Western Blot analysis of Iba-1
immunoreactivity in the ipsi lateral L4/5 mouse spinal cord dorsal horn 7 days after SNI and treatment with R-flurbiprofen (4.5 mg/kg twice daily) or
vehicle. Representative blot of n=4 per group. B. The densitometric ratio of Iba-1 versus loading control b-actin was used for statistics; P,0.05. b
Quantitative EIA analysis of phopho-p38 MAP kinase in the L4/5 mouse spinal cord dorsal horn ipsilateral to 7 days SNI or CCI and treatment with R-or
S-flurbiprofen (4.5 mg/kg twice daily), dexamethasone (positive control) or vehicle. c Respective representative Western Blot of phospho-p38 and
p38 alpha. d Immunofluorescence and e Western Blot analysis of microglia CD68 immunoreactivity in the spinal cord dorsal horn 7 days after nerve
injury and treatment with R-flurbiprofen (4.5 mg/kg twice daily) or vehicle ipsi lateral to the nerve lesion (n=3 per group). f, g CD11b
immunofluorescence of dorsal horn microglia and densitometric CD11b image analysis in the ipsilateral dorsal horn 21d after SNI. Scale bar: 100 mm.
doi:10.1371/journal.pone.0010628.g007
R-Flurbiprofen & Cannabinoids
PLoS ONE | www.plosone.org 13 May 2010 | Volume 5 | Issue 5 | e10628Since R-flurbiprofen also modulates gamma-secretase depen-
dent substrate processing [48] it was considered as potential drug
for slowing the progression of Alzheimer’s disease [7,49]. It is
unknown if this is mediated through modulation of endocanna-
binoids and if gamma-secretase is somehow involved in the
neuronal adaptations and glia activation that occur after
peripheral nerve injury.
In summary we demonstrated that R-flurbiprofen restored
endogenous cannabinoids that are diminished in DRGs and spinal
cord dorsal horn after a peripheral nerve injury. R-flurbiprofen
thereby enhanced the endogenous defense against neuropathic
pain, without direct cannabinoid receptor stimulation, therefore
presumably without tolerance or CB1-mediated central side
effects. The apparent lack of a specific target may well be an
advantage because it helps to avoid significant toxicity. R-
flurbiprofen is an interesting drug for patients with neuropathic
pain and may represent a lead compound for further research in
endocannabinoid-modulating-drugs.
Supporting Information
Figure S1 Time course of mRNA levels of cannabinoid-1
receptor (CB1) in the (a) L5 DRGs and (b) the dorsal horn of the
lumbar spinal cord ipsi lateral to a sciatic nerve lesion in three
different models of neuropathic pain, i.e. the spared nerve injury,
SNI, the chronic constriction injury, CCI and the spinal nerve
ligation, SNL analyzed by Affymetrix U34 microarray in triplicate.
Pooled samples of three animals each were used. The asterisks
indicate statistically significant results with P,0.05. 1c Composite
image of the spinal cord 7 days after nerve injury in animals
treated with vehicle. CB1 receptor red, microglia Iba-1 green,
neuronal NeuN blue.
Found at: doi:10.1371/journal.pone.0010628.s001 (0.11 MB
PDF)
Figure S2 Immunofluorescence of the glial fibrillary acidic
protein (GFAP) as a marker for astrocytes in the dorsal and ventral
horns of the spinal cord ipsilateral to a peripheral sciatic nerve
injury. Rats were dissected 4 weeks after the nerve injury (SNI
model) and 14 mm sections of the L4/5 spinal cord were cut on a
cryotome, incubated with anti-GFAP antibody and Alexa488-
labeled secondary antibody. Images were captured on a Nikon
fluorescent microscope. R-Flurbiprofen was administered twice
daily by i.p. injection (4.5 mg). Treatment was initiated one day
after nerve injury.
Found at: doi:10.1371/journal.pone.0010628.s002 (0.10 MB
PDF)
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